Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Cancer symbols : Tak save search
Non-Small Cell Lung Cancer (NSCLC) Market to Reach $29.95 Billion by 2028, Fueled by Advances in Therapy and Diagnostics
Published: 2024-02-22 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: 0.14%
H: 0.0%
C: -0.0%
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: 0.26%
H: 1.36%
C: 1.36%
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: -0.85%
H: 1.12%
C: 0.43%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.92%
H: 0.0%
C: 0.0%
UCBJY | $63.874 -4.38% 11K
|
Manufacturing
|
| O: 1.46%
H: 0.44%
C: 0.44%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -0.27%
H: 0.0%
C: -1.17%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.2%
H: 0.14%
C: -0.48%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.29%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: -0.69%
H: 1.42%
C: 1.22%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 2.37%
H: 1.51%
C: 0.79%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.65%
H: 1.63%
C: 1.48%
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: -0.88%
H: 1.46%
C: 1.13%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: 0.0%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: -2.81%
H: 2.08%
C: 1.38%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: -0.35%
H: 1.15%
C: 0.96%
lung reach cancer cell diagnostics therapy market
Blood Cancer Drugs Market Report 2023: Reveals Striking Growth Prospects with a Surge in R&D Activities - Long-term Forecasts to 2028 and 2033
Published: 2024-02-06 (Crawled : 00:00) - prnewswire.com
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
|
| O: -1.53%
H: 0.0%
C: 0.0%
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: -0.37%
H: 0.0%
C: 0.0%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
UCBJY | $63.874 -4.38% 11K
|
Manufacturing
|
| O: 1.71%
H: 1.28%
C: 0.94%
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: 0.28%
H: 0.18%
C: 0.0%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.07%
H: 0.42%
C: 0.07%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.09%
H: 0.39%
C: -0.36%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 1.47%
H: 0.0%
C: 0.0%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.76%
H: 4.31%
C: 2.11%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.14%
H: 0.35%
C: -1.12%
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: 1.48%
H: 0.0%
C: 0.0%
VRTX | $397.48 0.24% 0.23% 1.4M
|
Health Technology
|
| O: 0.15%
H: 2.4%
C: 0.56%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.33%
H: 0.0%
C: 0.0%
JAZZ | $110.9 0.29% 0.29% 580K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: -1.4%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: -0.4%
H: 0.19%
C: -0.33%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: -6.22%
report cancer blood growth market
United States Endometrial Cancer Research Report 2023
Published: 2024-02-02 (Crawled : 10:00) - prnewswire.com
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.21%
H: 0.49%
C: -0.9%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.5%
H: 0.26%
C: -1.03%
report cancer research
Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
Published: 2024-01-25 (Crawled : 22:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.27%
H: 0.07%
C: -0.07%
EXEL 4 | $22.695 0.2% 0.2% 1.8M
|
Health Technology
|
| O: 0.14%
H: 1.4%
C: -0.23%
ntact-02 asco cancer trial results
FRUZAQLA™ (fruquintinib) Now Available from Onco360 for the Treatment of Adult Patients with Metastatic Colorectal Cancer (mCRC)
Published: 2023-11-21 (Crawled : 18:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.07%
H: 0.57%
C: 0.0%
cancer treatment
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $9.09 -1.73% -1.76% 330K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.37 -0.46% 0.0% 460K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO M | $4.135 -0.12% -0.12% 750K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $67.76 -1.3% -1.31% 7.7M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL 4 | $22.695 0.2% 0.2% 1.8M
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
Published: 2023-08-21 (Crawled : 05:00) - globenewswire.com
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.4%
H: 0.6%
C: 0.47%
EXEL 4 | $22.695 0.2% 0.2% 1.8M
|
Health Technology
|
| O: 0.28%
H: 1.32%
C: 0.99%
ntact-02 positive cancer trial results
Global Cancer Therapies Strategic Business Report 2023: Industry Focuses on New Approaches to Treat Cancer
Published: 2023-06-27 (Crawled : 01:00) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.95%
H: 0.19%
C: -0.32%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.19%
H: 0.11%
C: -1.46%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: -0.01%
H: 0.16%
C: -0.32%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 0.03%
H: 0.12%
C: -0.24%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: -0.91%
H: 0.56%
C: -0.5%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 2.15%
H: 1.18%
C: 0.43%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.06%
H: 0.46%
C: 0.0%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: -0.21%
H: 0.42%
C: 0.13%
report business cancer treat global
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
Published: 2023-06-15 (Crawled : 14:20) - globenewswire.com
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.31%
H: 0.78%
C: 0.69%
HCM | $17.64 -1.34% -1.36% 63K
|
Health Technology
|
| O: 2.46%
H: 9.6%
C: 5.6%
authorization cancer application
Global Peptide Therapeutics Market Report 2023: Increasing Prevalence of Cancer and Metabolic Disorders Drives Growth
Published: 2023-06-08 (Crawled : 02:00) - prnewswire.com
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: 0.07%
H: 0.0%
C: -1.7%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: 1.32%
H: 0.0%
C: -0.62%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.62%
H: 0.88%
C: 0.81%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 1.26%
H: 1.08%
C: 0.91%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 0.41%
H: 0.68%
C: 0.64%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -0.11%
H: 2.66%
C: 2.24%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: 0.28%
H: 0.42%
C: -0.05%
BNTX | $87.88 1.62% 1.59% 750K
|
Health Technology
|
| O: 0.39%
H: 0.15%
C: -0.79%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: -0.23%
H: 1.83%
C: 1.52%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: 0.0%
H: 0.28%
C: -0.23%
metabolic report cancer global therapeutics growth market
Targeted Therapy Global Market Report 2023: Increasing Prevalence of Cancer Drives Growth
Published: 2023-05-15 (Crawled : 17:00) - prnewswire.com
GNMSF | $291.12 3.83% 300
|
Health Technology
|
| O: 0.24%
H: 0.66%
C: 0.66%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: 0.0%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.61%
H: 0.3%
C: 0.24%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.2%
H: 0.13%
C: -0.22%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 0.27%
H: 0.6%
C: 0.41%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
GMAB | $29.51 0.85% 0.85% 500K
|
Health Technology
|
| O: 0.38%
H: 0.91%
C: 0.69%
AMGN | $265.505 -0.66% -0.67% 1.7M
|
Health Technology
|
| O: 0.14%
H: 0.28%
C: 0.11%
report cancer global therapy growth market
HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer
Published: 2023-03-31 (Crawled : 01:00) - globenewswire.com
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.0%
H: 0.92%
C: 0.8%
HCM | $17.64 -1.34% -1.36% 63K
|
Health Technology
|
| O: -1.19%
H: 2.04%
C: -1.66%
fda cancer treatment submission
Endometriosis Drugs Global Market Report 2023: Emerging Treatments for Endometriosis & Endometrial Cancer Present Opportunities
Published: 2023-03-11 (Crawled : 04:20) - prnewswire.com
ALPMF | $9.48 43.47% 1.7K
|
Health Technology
| Email alert
Add to watchlist
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
| Email alert
Add to watchlist
AZNCF | $138.88 -4.19% 960
|
Health Technology
| Email alert
Add to watchlist
OBSV | $0.1018 -15.52% -18.95% 8.2M
|
Health Technology
| Email alert
Add to watchlist
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
| Email alert
Add to watchlist
ABBV | $161.67 -0.38% -0.04% 5.4M
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.55 -1.11% 300K
|
Manufacturing
| Email alert
Add to watchlist
global report cancer market
Global Head And Neck Cancer Therapeutics Market Report 2022: Sector to Reach $2.5 Billion by 2028 at a 12.3% CAGR
Published: 2023-01-12 (Crawled : 22:00) - prnewswire.com
SNYNF | $92.9 -2.18% 880
|
Health Technology
|
| O: -0.13%
H: 0.76%
C: 0.76%
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: 2.77%
H: 0.63%
C: 0.63%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.13%
H: 2.35%
C: 2.16%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: 0.13%
H: 1.04%
C: 0.57%
SNY | $46.22 0.63% 0.63% 1.7M
|
Health Technology
|
| O: 1.89%
H: 0.0%
C: 0.0%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: 1.27%
H: 0.78%
C: 0.15%
global report therapeutics cancer market
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 23:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
ntact-01 lung immunotherapy trial update cancer
Exelixis Provides Update on Phase 3 CONTACT-01 Trial Evaluating Cabozantinib in Combination with Atezolizumab in Patients with Metastatic Non-Small Cell Lung Cancer Previously Treated with Immunotherapy and Chemotherapy
Published: 2022-12-08 (Crawled : 22:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.07%
H: 1.09%
C: 1.09%
EXEL 4 | $22.695 0.2% 0.2% 1.8M
|
Health Technology
|
| O: 0.0%
H: 1.59%
C: 1.04%
ntact-01 lung immunotherapy trial update cancer
Global Cancer Therapies Market Report 2022: Market to Reach $209.2 Billion by 2026 - Industry Focuses on New Approaches to Treat Cancer
Published: 2022-08-03 (Crawled : 19:00) - prnewswire.com
GLAXF | $20.07 -14.18% 1K
|
Health Technology
|
| O: -1.22%
H: 1.8%
C: 1.8%
AZNCF | $138.88 -4.19% 960
|
Health Technology
|
| O: 2.52%
H: 0.0%
C: -0.19%
NVSEF | $93.6375 6.88% 82K
|
Health Technology
|
| O: -2.88%
H: 0.0%
C: -0.21%
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.29%
H: 0.72%
C: 0.58%
PFE A | $25.91 0.19% -0.04% 34M
|
Health Technology
|
| O: 0.08%
H: 0.29%
C: -0.08%
NVS | $94.41 0.95% 0.0% 1.4M
|
Health Technology
|
| O: 0.2%
H: 0.44%
C: 0.24%
JNJ | $147.59 0.05% 0.0% 8.5M
|
Health Technology
|
| O: 1.4%
H: 0.0%
C: 0.0%
GSK | $40.5 -0.39% -0.03% 2.8M
|
Health Technology
|
| O: 0.27%
H: 0.1%
C: -0.81%
LLY | $750.77 -0.12% 0.0% 2.3M
|
Health Technology
|
| O: -1.16%
H: 0.02%
C: -1.42%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: -0.27%
H: 0.22%
C: -0.92%
AZN | $68.75 -0.26% -0.26% 7.6M
|
Health Technology
|
| O: 1.13%
H: 0.35%
C: 0.35%
global report cancer market
Exelixis Announces Cabozantinib in Combination with Nivolumab and Ipilimumab Significantly Improved Progression-Free Survival in Phase 3 COSMIC-313 Pivotal Trial in Patients with Previously Untreated Advanced Kidney Cancer
Published: 2022-07-11 (Crawled : 13:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.91%
H: 0.35%
C: -0.21%
EXEL 4 | $22.695 0.2% 0.2% 1.8M
|
Health Technology
|
| O: 1.67%
H: 0.0%
C: -5.67%
osmic-313 kidney trial cancer phase 3 nivolumab
Exelixis Announces Detailed Results from Urothelial Carcinoma and Non-Small Cell Lung Cancer Cohorts of the COSMIC-021 Trial at ASCO 2022
Published: 2022-05-26 (Crawled : 00:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
EXEL 4 | $22.695 0.2% 0.2% 1.8M
|
Health Technology
|
| O: 0.11%
H: 0.0%
C: 0.0%
osmic-021 trial asco results cancer urothelial carcinoma
Exelixis’ Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Published: 2022-05-03 (Crawled : 18:00) - biospace.com/
TAK | $13.18 -1.42% 0.0% 1.8M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
BMY | $48.51 0.48% 0.0% 12M
|
Health Technology
|
| O: 0.36%
H: 0.0%
C: 0.0%
EXEL 4 | $22.695 0.2% 0.2% 1.8M
|
Health Technology
|
| O: 0.09%
H: 1.54%
C: -0.44%
cabometyx approval cancer
Gainers vs Losers
| 49% | 51% |
Top 10 Gainers
KAVL | $6.275 135.02% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.371 -5.12% 43.09% 3.3M
|
Health Technology
LGVN P 3 d | $2.94 73.96% 42.52% 57M
|
HUBC | $1.94 49.23% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
AMBI | $3.72 -26.77% 21.77% 9.8K
|
n/a
Your saved searches
Save your searches and get alerts when important news are released.